# Index

## A

active implantable medical devices (AIMDs) 183
biological safety 185
country-specific requirements 189–192
definition 184–194
electrical/electromagnetic safety 186
general standards 185–194
heat 186
markings and symbol requirements 187
mechanical safety 187
MRI imaging/medical treatments risks 186
radiofrequency communication 187
regulatory approval principles 187–188
sterilization and packaging 186
surgical technique validation 187
adverse event (AE)
national level reporting (devices) 211–217
advertising and promotion
for devices 216
Africa and Middle East
universal health coverage (UHC) 91
Africa and Middle East (AME) region
HTA implementation 91
regulatory organizations in 6–7
African Medicines Regulatory Harmonization (AMRH) 6
ALCOA+ 19
animal rule
for device conformity 141
APEC Life Sciences Innovation Forum (APEC LSIF)
IMDRF regional harmonization 4
Regulatory Harmonization Steering Committee (RHSC) 5
Argentina
device traceability and tracking 53
traceability and code for medicines 52–58
Asia
HTA adoption in 94–112
HTA status of selected countries 93
Asian Harmonization Working Party (AHWP)
harmonization efforts 5
IMDRF harmonization initiatives 4
Asian-Pacific Economic Cooperation (APEC) 5
Association of Southeast Asian Nations (ASEAN) membership of 4
Association of Southeast Asian Nations Pharmaceutical Product Working Group (ASEAN PPWG) 5
Australia
AIMD requirements 189–194
essential principles for IVDs 177–181
HTA process for reimbursement 101
HTA use in 98–112
IVD classification 176
IVD clinical trial requirements 176
IVD conformity assessment 177–181
IVD regulations 176–181
Rule 9 special classification 179

## B

biocompatibility
device materials 141
biological safety, AIMDs 185
Brazil 15
AIMD requirements 191
device INMETRO certification 20
GMP certificate for marketing 21
ICH Q7 adoption 15
ISO 13485 use 154–156
medicinal product serialization 53–58
budget-impact analysis (BIA) 81

## C

Canada
AIMD requirements 191
combination products 228–234
HTA implementation in 99
ISO 13485 compliance 153
IVD regulations 177–181
mandatory problem reporting for devices 216
public system reimbursement decision pathway 105
Canadian Agency for Drugs and Health Technologies (CADTH)
drug review process 102
elements and recommendations categories 103
HTA implementation 99
Canadian IVD regulations
classification 179–181
clinical trial requirements 179
Medical Device License (MDL) 179
cell-based medicinal products
good manufacturing and distribution practices 15
CE marking/certificates of compliance for compliance 154
Central Social Insurance Medical Council (Chuikyo) 98
certificate of compliance 21
chemical, physical, and biological properties for devices 115
chemistry, manufacturing and controls (CMC), TPLC approach 12
China
aligning with IMDRF UDI recommendations 54, 55
counterfeit and regulations 54–58
enforcement powers in 25
ICH Q7 adoption 15
serialization of medicinal products 54–58
China Food and Drug Administration (CFDA), medicinal product serialization 54
CLIA categorization
single laboratory 175
US IVD regulation 171–181
clinical decision support software (CDS) guidance 199
Clinical Effectiveness (EFF) 83
combination products 219
designation and premarket review 221
human factors 234
primary mode of action 221–234
product categories 223
regulatory challenges 220–234
combination products (Canada)
definition 228
designation and review 228–234
devices with medicinal product 229–234
postmarket requirements 229
regulatory pathway 228–234
combination products (EU)
ancillary medicinal product 230
consultation procedure 231
definition 229–234
devices administering medicinal products 231, 232
human factors 234
manufacturing, labeling, final release 234
transition to EU MDR 231
combination products (US)
constituent parts 222–234
designation and review 223–234
development considerations 224–234
FDA approved products 222
human factors 225–234
manufacturing regulations 226–234
postmarketing safety reporting 227
postmarketing safety reporting (PMSR) 227
compliance and enforcement (pharmaceutical products) 11
advertising and promotion 19–27
anti-corruption 20–27
electrical, environmental, and wireless device requirements 20–27
GMP requirements for 15
import alerts/distribution bans 24
market authorization requirements 21–27
recalls/market withdrawal/stock recovery 25
role of professional in 25–27
scope of regulations 12–27
surveillance 21–27
trade 20–27
conformity assessment
IVD devices 163
QMS requirements for devices 148
stages of 178
conformity assessment elements
Class A Device 120
Class B Device 120
Class C Device 121
Class D Device 121
device classification relationship 165
IVD devices 161–180
quality management system 147
corrective and/or preventive action (CAPA)
IVD premarket requirement 164
Corrective and preventive action (CAPA) for software 202
cosmetic products
regulatory requirements 3
Cost and Economic Evaluation (ECO) 83
cost-based pricing (CbP) model 62
cost–benefit analysis (CBA) 81
cost-effectiveness analysis (CEA) 81
cost-minimization analysis 81
cost-of-illness analysis 81
cost-utility analysis (CUA) 81
counterfeit and regulation
European legal requirements 44–58
exemptions by individual states 47
international 33
legal actions for control of 36
occurrence and prevention of 34–55
reported substandard/falsified products 51
rest of the world 50–58
risk reduction methods/traceability 37
terminology for 35
terminology inconsistencies 34
US legal requirements 36–58
cybersecurity, for device software 203

danish centre for HTA (DACEHTA) 82
debarment 24
Declaration of Conformity
device premarket requirements 118
for IVDs 164
Table of Contents (ToC) format for RPS 139
Description and Technical Characteristic of Technology (TEC) 83
design qualification (DQ), GHTF guidance 154
device classification
active device decision tree 131, 132
additional rules 133
device class and rules 161
invasive device classification decision tree 129, 130
IVD device classification 159
noninvasive classification decision tree 128
device conformity assessment 117
device Identifier (DI) 42
device package, definition 43
device premarket requirements
active devices 126
additional rules 127
classification rules 122
conformity assessment principles 117
declaration of conformity 118–122
design and manufacturing requirements 115–122
device definition 114–122
harmonized conformity assessment procedures 119
invasive devices 124
manufacturer/device registration 119
medical devices classification principles 122
noninvasive devices 123
Quality Management System (QMS) 118–122
registration with regulatory authorities 119
safety and performance requirements 114–122
standards in medical device assessment 122
summary technical documentation 118–122
device registration, IVD devices 165
diagnostic or measuring function of devices 116
direct-to-consumer (DTC) advertising and promotion
prescription drug advertising 19

E
Economic Community of West African States (ECOWAS)
member 6
Egypt, pricing of medical services 93
energy source connection for devices 116
England
HTA programs/bodies in 87
process map for 90
environmental standards, IVDs 166–181
essential health service package (EHSP) 94
essential principles, device safety and performance 114
Ethical Analysis (ETH) 83
Ethiopia, EHSP implementation 94
EUDAMED
device lifecycle information 49
EU-level Transparency Committee 61
EUnetHTA 83
Eurasia, implementation of harmonization in 4
Eurasian Economic Union (EAEU/EEU), harmonization 5
European Collaboration on Health Technology Assessment (ECHTA) 82
European Commission (EC)
HTA studies 82
ICH Q7 adoption 15
initiatives on pricing and reimbursement 61
medicinal price/reimbursement controls legal framework 60–77
software as medical device 197
Transparency Directive update 60
European Conformity (CE) Mark
for software 202
postmarket surveillance system requirements 210
European Falsified Medicines Directive (FMD)
aims and scope of 44–55
requirements 44–55
European Medicines Agency (EMA)
post inspection certificates 24–27
product quality defect reporting 25
European Network for Health Technology Assessment (EUnetHTA) Project 82
European Union (EU)
  AIMD requirements 189
  combination products 229–234
  EUDAMED 49–58
  European Falsified Medicines Directive 44–58
  EU Unique Device Identifier (UDI) System 48–58
  HTA development in 82
  inspection process 22–27
In Vitro Diagnostic Medical Device Regulation 167
ISO 13485 compliance 154–156
medical device software requirements 204
postmarket surveillance system 210
pricing and reimbursement 59, 59–77
pricing and reimbursement models used in 62–77
pricing and reimbursement policies 59–60
software classification 200–207
software regulation 197–207
VICH program 4
EU Unique Device Identifier (UDI) System
  aims and scope of 48–55
  Basic EU UDI-DI definition 49
  implementation timeline 50–55
  implications and challenges 50–55
  labeling requirements 49–55
  requirements and implementation 49–55
  evidence-based guidance, NICE use of 87
  evidence-based international standards 7

F
Falsified Medicines Directive (FMD)
  implementation 46–55
  implications and challenges 47–55
  supply chain stakeholder requirements 45
  third countries 48
  timeline for implementation 47–55
FDA-accredited issuing agency (IA) 42
Federal Trade Commission (FTC), false claim regulation 20
Field Safety Corrective Action (FSCA), reasons for 214
field safety notices (FSNs), content and actions required 215–217
foods, dietary supplements, and cosmetics, regulatory history and requirements 3
France
  healthcare delivery and funding 67
  HTA comparison with EU countries 92

G
Germany
  healthcare delivery and funding 69
  HTA comparison with EU and UK 92
  process map for 86
global atlas of medical devices 2
Global Harmonization Task Force (GHTF)
  device classification principles 161
  history 4
  QMS guidance 154
  submission structure 187
Global UDI Database (GUDID) 42
good clinical practice (GCP)
  compliance and 14–27
good distribution practice (GDP)
  certificates for 18
  requirements for 17–27
good documentation practices (GDocP) 18–27
good laboratory practices (GLP)
  scope of nonclinical studies 13–27
good manufacturing practice (GMP) 226
  combination products (US) 226
  definition and scope of 15–27
good pharmacovigilance practices (GPvP) 18, 18–27
GS1 Global Location Number (GLN) 53
GS1 Healthcare Reference Guide 53
Gulf States/Region
  HTA implementation 93

H
harmonization
  ASEAN PPWG 5
  device conformity assessment procedures 119
  EU HTA 87–91
  Eurasian Economic Union (EAEU/EEU) 5
  history of 3
  ICH Q7 for GMP 15
  IEC 62304 in US and EU 201
  IMDRF regional initiatives 4
  of inspection process 23
  regulatory and payer approval 59
  unique device identification system 165–181
  WHO initiatives 7
Health Canada (HC)
  pharmacovigilance practices 18
  healthcare products 12
  counterfeit and regulations 33
  development process for 12
healthcare professionals (HCPs) advertising to 20
health effects evaluations 65
Health Policy Forum (HPF) in MENA 93
Health Problem and Current use of Technology (CUR) 83
Health Technology Assessment (HTA) 79
  comparison of EU countries and UK 92
definition 79
development in EU 82
domains within 83
economic analysis used in 81
health product market access 80
history 80–81
models used in EU 83
organization and structure of HTA Bodies 83–91
pricing and reimbursement 63
role in decision-making in EU 86–91
UK 88
UK and EU comparison 90–91
use in decision making 80
Highly Specialised Technologies (HST) evaluations 74
HTA bodies (HTABs) 80
HTA Core Model 83
human factors
  combination products 234
  IEC 62366 standard 234

I

IEC 62366, human factors standard 234
import alerts/distribution bans 24
India
  device classification and UDI use 52
  track-and-trace and barcode for medicines 51–58
indirect medical purpose 167
infection and microbial contamination risk for devices 115
infringement on intellectual property 34
INMETRO certification (devices) 20
inspections
  by FDA 22
  harmonization of 23
  IVD PMS 164
  postapproval inspections 21
  preapproval, by regulatory authority 21
Inspectorates Association 23
installation qualification (IQ), GHTF guidance 154
instructions from manufacturer for device 116
integral drug-device combination (iDDC) products 232
intellectual property (IP) infringement, during design phase 36
intended use
  “indirect medical purpose” 167
  in software regulation 196
  laboratory developed tests 175
  “lifestyle tests” 167
International Coalition of Medicines Regulatory Authorities (ICMRA) membership 6
International Cooperation on Harmonisation of Technical Requirements for Registration of Veterinary Medicinal Products (VICH) 4
International Council for Harmonisation (ICH)
history 3
  ICH Q7 guideline 15
  pharmacovigilance definition 2
  TPLC lifecycle 12
International Electrotechnical Commission (IEC) 62304,
  software lifecycle process 201
International Generic Drug Regulators Programme (IGDRP), consolidation with IPRF 6
International Medical Device Regulators Forum (IMDRF)
harmonization 4
MDSAP pilot 4
National Competent Authority Report (NCAR) Exchange Program 3
  recommended UDI framework 50
Regulated Product Submission program 164
software/device definitions 196
software guidance 196
Table of Contents (ToC) format 21, 136
International Network of Agencies for Health Technology Assessment (INAHTA) 80
International Organization for Standardization (ISO)
guidance for software 196
  ISO 10993 185–186
  ISO 13485 12, 149, 154, 152–156, 214
  ISO 14971 188, 214
International Pharmaceutical Regulators Forum (IPRF)
consolidation of 6
  implementation of harmonization 4
International Pharmaceutical Regulators Programme (IPRP)
history and benefits of 6
International Society for Technology Assessment in Health Care (ISTAHC) 80
investigational device exemption (IDE)
  de novo classification 174–181
  software or firmware 174
in vitro diagnostic devices (IVDs) 159
Class A device 165
Class B device 166
Class C device 167
classification principles 160
classification rules 162, 163
conformity assessment elements 163
conformity assessment stages 178
Declaration of Conformity 164
definition 160, 169
device risk class and requirements 161
GHTF classification system 161
PMS and vigilance requirements 168
quality management system 164
regulatory changes for 168–181
technical documentation 164–180
US regulation 169–181
ISO 10993 standard, protection from biological risk 185–186
ISO 13485
2016 requirements 150
CE marking/certificates of compliance for compliance 154
historical perspective 149
in regulatory systems 152–156
postmarket surveillance for devices 214
quality management systems for devices 15
ISO 14971
AIMD risk management 188
postmarket surveillance procedures 214
ISO/IEC 17025 certification 14
Italy
healthcare delivery and funding 72
HTA comparison with EU countries 92

J
Japan
drug/device pricing framework 100
HTA emphasis in 98
HTA pilot evaluation of products 97
ICH Q7 adoption 15
VICH program 4
Jordan, HTA implementation in 93

K
Kenya, HTA implementation 94
Korea Fair Trade Commission 20

L
labeling requirements
AIMDs 188
EU FMD requirements 49
under US UDI rule 43
laboratory developed tests (LDTs)
intended use 175
risk-based classification 175
Latin America (LATAM)
country-specific HTA overview 104
HTA development 100–112
HTA timeline in 106
laws, regulations, and guidance covered
active implantable medical devices (AIMDs) 183
combination products 219
Health Technology Assessment (HTA) 79
international counterfeit and regulation 33
international harmonization 1
in vitro diagnostic devices 159
medical device premarket requirements 113
medical device quality management systems 147
postmarket requirements for devices 209
reimbursement and pricing 59
software 195
technical and regulatory requirements (devices) 135
lifecycle management (LCM)
combination products (EU) 233–234
device postmarket surveillance system 210
device technical file 216
for IVDs 168–181
software 201
"lifestyle tests" 167

M
Malaysia
HTA adoption in 95–112
Malaysian Health Technology Assessment Section (MaHTAS) 95
1995–2018 impact 95
historical milestones 96
manufacturing and environmental properties for devices 115
manufacturing/manufacturer
AIMD process validation 188
combination products (US) 226–234
device design and requirements 115–134
IVD device registration 165
IVD lifecycle management 168
periodic reports from 216
quality control requirements in 14
reporting requirements for devices 217
requirements for compliance 12
marketing authorization application (MAA)
applicability of GxPs 22
applicability of GxPs 22
certificate of compliance 21
HTA in 80
platform iDDCs 232
marketing authorization holder (MAH)
compliance by 22
compliance requirements 12
market withdrawal 25
mechanical risk protection for devices 116
medical device conformity assessment elements, quality management system 147–156
medical device data systems (MDDS) 196
medical device quality management system (MDQMS) 147
conformity assessment requirements 148
design and development control steps 152
design controls on the design process 153
interrelated processes 148
ISO 13485 historical perspective 149–156
ISO 13485 in regulatory systems 152–156
medical device conformity assessment elements 147
PDCA methodology 149
process validation 154–156
QMS vs GMP 148–156
medical devices
active implantable medical devices 183
combination products 219
essential principles of safety and performance 114
EU risk classification 119
GHTF risk classification 119
in vitro diagnostic devices 159
postmarket requirements 209
premarket requirements 113
quality management systems 147
regulatory history 2
regulatory requirements 135
safet and efficacy studies for 14
technical and regulatory requirements 135
US device classification 119
Medical Device Single Audit Program (MDSAP) Pilot 4
Medicines and Healthcare products Regulatory Agency (MHRA)
refusal to grant inspection 24
Member States (EU)
medicinal product pricing 60
postapproval inspection responsibility 21
pricing and reimbursement in 59
meningitis B vaccine pricing 59
Middle East and North Africa (MENA) countries
health policy network in 93
HTA implementation 91
Ministry of Health, Labour and Welfare (MHLW)
ICH Q7 adoption 15
Multiple Technology Appraisal (MTA) 74

N
National Competent Authority Report (NCAR)
exchange criteria and report format 211–217
Exchange Program 3
National Coordinating Centre for Health Technology Assessment (NCCHTA) 73
National Evidence-based healthcare Collaborating Agency (NECA) 98
National Health Insurance (NHI) system (South Korea) 95
National Health Service (NHS) 73
National Health Service (NHS), NICE as advisory body to 87
National Institute for Health and Care Excellence (NICE) 73, 87
National Institute for the Control of Pharmaceutical and Biological Products (NICPBP) 54
National Insurance (NI) 73
National Medical Products Administration (NMPA)
ICH Q7 adoption 15
UDI device identification rules 54
New Zealand
prescription drug advertising 19
nonclinical studies
pharmaceutical/medicinal products 14
North America
HTA development in 99–112
Northern Ireland, HTA use in 87
notified body opinion (NBOp) 232

O
off-the-shelf (OTS) software, guidance on use 199
oncology products, EMA authorization and HTA decision 89
operational qualification (OQ), GHTF guidance 154
Organisational Aspects (ORG) 83
Organisation for Economic Co-operation and Development (OECD)
evidence-based international standards 7
Organisation of Islamic Cooperation (OIC), membership 7
outsourcing of software 202
over-the-counter (OTC) products
advertising of 19

P
Pan American Health Organization (PAHO)
IMDRF status 4
Pan-American Network on Drug Regulatory Harmonization (PANDRH)  
regulatory authority membership 5  
Patient-Centered Outcomes Research Initiative (PCORI) 99  
Patients and Social Aspects (SOC) 83  
performance and clinical evaluation 117  
Pharmaceutical Inspection Co-operation Scheme (PIC/S)  
history 3  
Pharmaceutical Inspection Cooperation Scheme (PIC/S)  
compliance requirements 15–27  
GMP inspections 23  
pharmaceutical products  
regulatory history of drugs 2  
Pharmaceuticals and Medical Devices Agency (PMDA)  
HTA in reimbursement prices 98  
ICH Q7 adoption 15  
pharmacovigilance  
elements of 2  
WHO definition 2  
postmarket requirements (devices) 209  
combination products (US) 227  
criteria for competent authority reporting 212  
distribution records for traceability 211  
FSCA and CAPA plans 214–217  
periodic reports 216  
postmarket surveillance activities 214–217  
vigilance reporting in PSSS 210–217  
postmarket surveillance system (PMSS), devices in EU 210  
postmarket surveillance/vigilance system (PMS)  
combination products (EU) 233–234  
for IVDs 164  
premarket approval application (PMA)  
AIMDs 190  
IVDs 173  
premarketing authorization (PMA) holders  
compliance by 22  
Premarket Notifications (510(k), IVDs 173  
premarket requirements  
medical devices 113  
pricing and reimbursement  
competent authorities 74  
cost-based (CbP) model 62  
current trends 66  
economic evaluations of treatments 64  
EU pricing and reimbursemens 62–77  
European Union 59  
health effects measurement 65  
HTA-models case studies 66–78  
reference-based pricing model 62  
value-based pricing model 62  
primary mode of action (PMOA) 221  
primary subject matter expert (SME) 25  
process validation  
biological safety 141  
components of 154  
decision tree for 154  
steps involved 154  
process validation (device QMS)  
facility and equipment validation 155–156  
process validation decision tree 155  
supplier control 157  
Validation Master Plan (VMP) 155  
production Identifier (PI) 42  
product manufacturers (510(k), compliance 22  
protection against radiation from devices 116  
Q  
Quality-Adjusted Life Year (QALY) 65, 89  
Quality Management System for devices (MDQMS),  
conformity assessment element 147  
quality management system (QMS)  
demonstration of supplier control 156  
device premarket requirements 118–122  
inspections of 21  
medical devices 147  
product/services from suppliers 156  
R  
recalls 25  
reference-based pricing model 62  
Regulated Product Submission (RPS)  
device harmonization initiative 136  
format for IVD/non-IVD 142  
IMDRF program 164  
regulations  
globalization effects on 7  
regulators’ role, statements of responsibility 2  
regulatory affairs  
history of 1  
Regulatory Harmonization Steering Committee (RHSC) 5  
regulatory professional, role of  
communication with regulators 25  
inspection support 26–27  
professional ethics 26  
system owner and SME 25–27  
risk assessment/management  
analysis for AIMDs 188
S

Safety (SAF) 83
Saudi Arabia
  HTA for high-cost drugs 91
Scotland 89
  HTA programs/bodies in 87
  process map for 91
Scottish Health Technologies Group (SHTG) 87
Scottish Medicines Consortium (SMC) 87
self-testing devices, intended use 160
self-testing or self administration device risks 116
software 195
  as device vs. standalone 196
  as regulated medical device 196–207
  categories and classification 200–207
  decision tree for EU MDR 198
  development of 201–207
  FDA precertification program 203
  in IVDs 174
  personal health data protection 203–207
  quality management system 202
  types and EU qualification 205
  software as a medical device (SaMD), definition/
  characteristics 196
South Africa
  HTA implementation 94
South Korea
  barcode or RFID tag for medicines 53–58
  HTA flow diagram 98
  HTA introduction in 95–112
  National Evidence-based healthcare Collaborating
  Agency (NECA) 98
  UDI framework for devices 53
Spain
  healthcare delivery and funding 71
  HTA comparison with EU countries 92
  standard operating procedures (SOPs)
    equipment and process validation 155
    equipment related 155
    process-related 156
  sterilization validation 141
  stock recovery 25
Sub-Saharan African countries, HTA implementation 91, 93
sulfathiazole tablets 15
Summary Technical Documentation (STED) guidance
  118, 136
supplied energy or substance risks 116
Sweden, value-based pricing in 66

Swedish Council on Technology Assessment in Health
  Care 82
  system owner 25

T

Table of Contents (ToC) format 21, 136
  clinical evidence (Chapter 4) 142–144
  harmonization for IVD submissions 164
  labeling and promotional material (Chapter 5) 142–144
  non-clinical evidence (Chapter 3) 140–144
  regional administrative (Chapter 1) 138–144
  submission context (Chapter 2) 139–144
technical and regulatory requirements for devices
  corrective and preventive actions 143
  design and development and planning 143–144
  essential technical file elements 136–144
  GHTF submission guidance by device class 137
  outsourcing 143
  postmarket use of STED 138
  risk management principles 143–144
  RPS documentation/ToC requirements 137–144
  RPS format 142
  use of standards 142–144
  verification and validation 140
technical file/design dossier elements
  postmarket phase 136
  premarket phase 136
  submission before market entry 136
technology appraisal (TA) committees (NICE) 87
technology assessment in HTA 80
thalidomide 15
The Americas
  harmonization organizations in 5–7
  HTA implementation in North America 99–112
ToC Chapter 1
  Declaration of Conformity 139
  topics covered 138–145
ToC Chapter 2
  device description 139–145
  global market history 139
  indications/intended use 139
  similar/previous device generations 139
ToC Chapter 3
  animal studies for device conformance 141
  biological safety 141
  Essential Principles checklist 140
  materials biocompatibility 141
  medicinal substances in device 141
  product verification and validation 140
risk management 140
software verification and validation 141
sterilization validation 141
ToC Chapter 4, clinical evidence of EP conformity 142
ToC Chapter 5, labeling and promotional material 142
total product lifecycle (TPLC) approach/methodology 12
vigilance in 18
Tunisia, HTA implementation 93
Turkey
  serialization of medicines in 54–58
  UDI-like system for devices 54

U
unique device/drug identification (UDI)
  global harmonization 165
  IMDRF guidance on 50
  in prevention of counterfeit/falsification 36
United Kingdom (UK) 23
  EU-UK Trade and Cooperation Agreement 61
  healthcare delivery and funding 73–77
  HTA comparison with EU countries 92
  HTA programs in 87–91
  Joint Committee on Vaccination and Immunisation (JCVI) 59
  surveillance approach in 23
  value-based pricing 66
United States (US)
  AIMD requirements 190–194
  combination products 222–234
  false claim regulation 20
  HTA implementation 99–112
  “HTA-like bodies” 102
  IVD regulations 169–181
  prescription drug advertising 19
  QSR for quality management 153–156
  recalls, classification of 25
  software regulation 197
  VICH program 4
United States (US) medical device reporting
  importers 217
  legal framework 217
  user facilities requirements 217
  unregulated software 200
US Drug Supply Chain Security Act (DSCSA) 36
  aims and scope of 36–58
  dispensers’ implementation of 39–58
  implementation for dispensers 39–58
  implications and challenges of 41
  terminology and stakeholders definitions 38

US Food and Drug Administration (FDA)
  civilmoney penalties for noncompliance 24
  commercialization/post commercialization regulation 21–27
devarment 24
  ICH Q7 adoption 15
  medical device GMPs 15
  oversight of IVDs 169
  post inspection observations 23
  Postmarket Surveillance Studies Program 214
  QSR and ISO 13485 152
  software classification revision 199–200
  software precertification program 203
timeline counterfeit and regulation implementation 40
Warning Letters 24

US IVD regulation
  Class I (general controls) 170–181
  Class III (premarket approval) 171–181
  Class II (special controls) 171–181
  CLIA categorization 171–181
cybersecurity with 175
definitions 169–181
  investigational device exemption 174–181
  oversight of 169
  postmarket surveillance 175
  premarket submission types 173–181
  presubmission program 172–181
  risk-based classification 170
US Unique Device Identifier (UDI) System Rule
  aims and scope of 42–55
  definition and requirements for 42–55
  implementation and implications of 43
  requirements and implementation 42–55

V
validation, facility and equipment 155
Validation Master Plan (VMP) 155
value-based pricing model 62
Vanessa’s Law 18
verification and validation
  AIMD submissions 188
device software 141
device sterilization 141
documentation for devices 140
veterinary medicinal products
  regulatory history 3

W
Wales, HTA use in 87
willingness-to-pay threshold 65
World Health Organization (WHO)
advertising and promotion recommendations 19
counterfeit products 34
country and regional offices of 6
data and record management 19
global atlas of medical devices 2
Global Surveillance and Monitoring System 50
good manufacturing practices draft 15
health technology definition 79
HTA definition 63
IMDRF status 4
pharmacovigilance definition 2
price transparency on vaccines 60